Recurrent low-grade gliomas: the role of fractionated stereotactic re-irradiation

被引:33
作者
Combs, SE
Ahmadi, R
Schulz-Ertner, D
Thilmann, C
Debus, J
机构
[1] German Canc Res Ctr DKFZ, Dept Radiat Oncol, D-69120 Heidelberg, Germany
[2] Univ Heidelberg, Dept Neurosurg, Heidelberg, Germany
关键词
astrocytoma; oligoastrocytoma; oligodendroglioma; overall survival; radiation; recurrent low-grade glioma;
D O I
10.1007/s11060-004-2029-z
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose: To assess the effectiveness of re-irradiation in recurrent low-grade gliomas (LGG). Patients and methods: Sixty-three patients were treated with fractionated stereotactic re-irradiation in the case of recurrent gliomas. At primary diagnosis of the tumor, the histology was grade II astrocytoma, oligodendroglioma or oligoastrocytoma. Fifty-two (82.5%) recurrences were in-field, three (4.8%) were localized at the field border, and eight (12.7%) tumors were localized completely out-field of the former RT field, respectively. Using three to four irregular non-coplanar fields formed with a multi-leaf-collimator, we applied a median total dose of 36 Gy (range 15 - 62 Gy) with a weekly fractionation of 5 x 2 Gy/week depending on the size and the location of the lesion. No concomitant chemotherapy was applied. Results: Radiation was well tolerated by all patients. No severe side effects occurred. Median overall survival was 111 months (range 12 - 240 months). Extent of neurosurgical resection significantly influenced overall survival (P = 0.02). Median interval between the first radiation therapy and re-irradiation was 50 months (range 5 204 months). From the time point of re-irradiation, median survival was 23 months. Median progression-free survival from the time point of re-irradiation was 12 months (range 2 - 63 months). No prognosticators could be identified for survival from re-irradiation and progression free survival. Conclusion: Our retrospective data suggest that stereotactically guided fractionated re-irradiation in recurrent glioma represents an effective treatment option with good results and few complications. However, further investigation is warranted to consolidate these results and to combine radiation with chemotherapy in the case of recurrent LGG.
引用
收藏
页码:319 / 323
页数:5
相关论文
共 52 条
[1]  
BERGER MS, 1994, CANCER, V74, P1784, DOI 10.1002/1097-0142(19940915)74:6<1784::AID-CNCR2820740622>3.0.CO
[2]  
2-D
[3]  
BRADA M, 1994, NEUROONCOLOGY ITS IM, P91
[4]   Factors influencing survival in high-grade gliomas [J].
Buckner, JC .
SEMINARS IN ONCOLOGY, 2003, 30 (06) :10-14
[5]   CHEMOTHERAPY FOR ANAPLASTIC OLIGODENDROGLIOMA [J].
CAIRNCROSS, G ;
MACDONALD, D ;
LUDWIN, S ;
LEE, D ;
CASCINO, T ;
BUCKNER, J ;
FULTON, D ;
DROPCHO, E ;
STEWART, D ;
SCHOLD, C ;
WAINMAN, N ;
EISENHAUER, E .
JOURNAL OF CLINICAL ONCOLOGY, 1994, 12 (10) :2013-2021
[6]   LOW-GRADE GLIOMA - TO TREAT OR NOT TO TREAT [J].
CAIRNCROSS, JG ;
LAPERRIERE, NJ .
ARCHIVES OF NEUROLOGY, 1989, 46 (11) :1238-1239
[7]   Understanding low-grade glioma - A decade of progress [J].
Cairncross, JG .
NEUROLOGY, 2000, 54 (07) :1402-1403
[8]   Single dose versus fractionated stereotactic radiotherapy for recurrent high-grade gliomas [J].
Cho, KH ;
Hall, WA ;
Gerbi, BJ ;
Higgins, PD ;
McGuire, WA ;
Clark, HB .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 1999, 45 (05) :1133-1141
[9]   Survival analysis part I: Basic concepts and first analyses [J].
Clark, TG ;
Bradburn, MJ ;
Love, SB ;
Altman, DG .
BRITISH JOURNAL OF CANCER, 2003, 89 (02) :232-238
[10]  
COMBS SE, UNPUB STEREOTACTIC R